Walmart ramps up its telehealth services by acquiring MeMD
Walmart ramps up its telehealth services by acquiring MeMD
… Walmart Enters The Telehealth Sector With A Major Strategic Deal …

Walmart fortifies its position as a growing healthcare provider organization and telehealth competitor

John G. Baresky

Terms of the deal have not been revealed yet but Walmart (NYSE: WMT) has disclosed it is acquiring telehealth innovator MeMD. Founded in 2010, MeMD is a recognized leader in telehealth services nationwide.


$20.9 Billion Deal: Thermo Fisher Scientific Buys PPD
$20.9 Billion Deal: Thermo Fisher Scientific Buys PPD
… Thermo Fisher Scientific Acquires PPD …

Thermo Fisher Scientific’s transformation by acquisition continues

Thermo Fisher Scientific (NYSE: TMO) has announced plans to acquire PPD (NASDAQ: PPD) for about $17.4 billion plus the assumption of PPD’s debt which stands around $3.5 billion.

The combination of the two companies pairs two global giants in healthcare diagnostics, medical research and clinical services. Thermo Fisher Scientific is an established leader in diagnostic and medical equipment technology while PPD is one of the largest contract research organizations (CROs) in the world.


AXA and Microsoft developing telehealth services
AXA and Microsoft developing telehealth services
… AXA goes all-in on telehealth in collaboration with Microsoft …

Two global business leaders join forces to launch a large scale virtual health platform

John G. Baresky

Paris-based financial services and insurance giant AXA (OTCMKTS: AXAHY) has selected enterprise technology leader Microsoft (NASDAQ: MSFT) as its partner to build a full-strength telehealth program for its clients and their members.

AXA is one of the largest health insurers in the world. Its plans provide medical coverage to more than 105 consumers and patients in 57 countries. AXA generated about $117.5 billion in sales during 2020.

Microsoft and AXA are developing a vast telehealth platform

AXA has no small plans for its telehealth initiative. …


Sleep Sensing is a new innovation in the latest version of Google Nest Hub …
Sleep Sensing is a new innovation in the latest version of Google Nest Hub …
… Google introduces Sleep Sensing in the new Google Nest Hub …

New Nest Hub “Sleep Sensing” application provides an array of rest quality monitoring measurements

John G. Baresky

Google, a business unit of Alphabet (NASDAQ: GOOGL) has introduced a new generation of Nest Hub technology that will help its users monitor the quality of their restfulness. The new Nest Hub combines several ambient sensory technologies to provide composite insights to user sleep patterns with its opt-in Sleep Sensing program.

Google is addressing an important underlying healthcare issue as the Centers for Disease Control and Prevention estimates about 70 million people in the United States do not get enough sleep.

Sleep Sensing works in several ways to measure rest quality levels

The new Nest Hub Sleep Sensing application monitors and compiles data from several human rest and…


Pfizer COVID-19 clinical trials: antiviral PF-07321332 and Pfizer antiviral PF-07304814
Pfizer COVID-19 clinical trials: antiviral PF-07321332 and Pfizer antiviral PF-07304814
… Pfizer researching oral and IV COVID-19 antiviral therapies PF-07321332 and PF-07304814

Pfizer seeks to expand COVID-19 drug portfolio by creating novel antivirus therapies

John G. Baresky

Pfizer seeks to expand COVID-19 drug portfolio by creating novel antivirus therapies

Global pharmaceutical giant Pfizer (NYSE: PFE) is evaluating antiviral product pipeline candidates to treat COVID-19 via oral administration as well as IV therapy.

The promising new oral drug candidate, designated as PF-07321332, is being evaluated in a Phase 1, randomized, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study to evaluate its safety, tolerability, and pharmacokinetics in healthy adult patients.

PF-07321332 is a protease inhibitor

The experimental compound is classified as a protease inhibitor. Protease inhibitors prevent viruses from multiplying by selectively binding to viral proteases and blocking the proteolytic cleavage of protein precursors that are required for viruses to replicate.

Protease inhibitors…


Grand Rounds and Doctor On Demand Merge Their Enterprises
Grand Rounds and Doctor On Demand Merge Their Enterprises
… Grand Rounds and Doctor On Demand Team Up …

Telehealth growth opportunities surge ahead as competition mounts

John G. Baresky

Grand Rounds and Doctor On Demand have announced plans to merge and form a larger, more competitive enterprise as the telehealth wave sweeps across the United States and global markets. The market valuation of the combined companies is reportedly over $2 billion.

Once combined, the new organization will have about 1,500 workers as Grand Rounds employs more than 600 staff members and Doctor On Demand has over 900 employees. Grand Rounds, founded in 2012 and Doctor On Demand, started in 2013, are both headquartered in San Francisco, California and privately held.

Grand Rounds will be the primary…


USDA provides $43 million in funding for rural medicine and education
USDA provides $43 million in funding for rural medicine and education
… New funding from the USDA for rural healthcare and education is a step in the right direction …

Funding is welcome but more is needed to reverse the issues in rural healthcare and academics

John G. Baresky

The USDA has announced it is funding 86 projects through the Distance Learning and Telemedicine (DLT) grant program. It helps rural healthcare organizations and rural educators improve their connections with and better support their patients or students. The new flow of monies is largely attributed to new demands and issues triggered by the COVID-19 pandemic.

To stay viable, rural communities require significant technology investment to support medicine, academics and business

The healthcare, education and commerce elements of rural America were already experiencing significant issues and disadvantages before the emergence of the coronavirus in the United States.

Numerous rural hospitals and other medical care provider organizations have closed at a record pace due…


Cosela (trilaciclib) is a new FDA-approved oncology therapy manufactured by G1 Therapeutics
Cosela (trilaciclib) is a new FDA-approved oncology therapy manufactured by G1 Therapeutics
… New G1 Therapy Cosela (trilaciclib) is an important new therapy for oncology …

New oncology therapy indicated for use in the treatment of small cell lung cancer

John G. Baresky

The U.S. Food and Drug Administration (FDA) has approved a new oncology therapy developed by G1 Therapeutics. Cosela (trilaciclib) earned an indication from the FDA to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

G1 Therapeutics expects the product to be available to the marketplace in March 2021.

Cosela is a unique and advanced cancer therapy

Cosela is the first and only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small-cell lung cancer being treated with chemotherapy.

The product is a kinase inhibitor that…


Robert Davis New CEO At Merck
Robert Davis New CEO At Merck
… Merck names Robert Davis as new CEO …

Present Merck CEO Kenneth Frazier is retiring in June

John G. Baresky

Global pharmaceutical giant Merck (NYSE: MRK) has named Robert Davis as their next chief executive officer. Davis joined Merck as a chief financial officer in 2014.

Globally known and respected, Merck chief executive officer Kenneth Frazier is retiring

The company’s present CEO, the legendary Kenneth Frazier, is retiring in June. Frazier has been a prolifically successful leader at Merck and is one of the few black Fortune 500 CEOs. Ken will continue to serve on Merck’s board of directors as executive chairman during the course of a transition period.


ViiV Healthcare Launches New HIV Therapy Cabenuva
ViiV Healthcare Launches New HIV Therapy Cabenuva
… ViiV Healthcare Launches New HIV Therapy Cabenuva …

GlaxoSmithKline, Pfizer and Shionogi enterprise continues to advance its HIV-focused business mission and develop breakthrough treatments

John G. Baresky

ViiV Healthcare, a company exclusively devoted to the HIV/AIDS marketplace, has announced the FDA has approved its latest new injectable therapy combination Cabenuva (cabotegravir and rilpivirine).

The FDA also approved Vocabria (cabotegravir) which is an oral tablet formulation of Cabenuva. Voacabria should be taken in combination with oral rilpivirine (Edurant) for one month prior to starting treatment with Cabenuva to ensure the medications are well-tolerated before switching to the extended-release injectable formulation.

Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies…

Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store